Local Institution - 0042
Bucharest, Romania
8 recruiting
Showing 1–16 of 16 trials
Recruiting
Phase 3
A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2)
Alzheimer s Disease
Bristol-Myers Squibb586 enrolled123 locationsNCT06976203
Recruiting
Phase 3
A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)
Non-small Cell Lung Cancer (NSCLC)
Bristol-Myers Squibb850 enrolled254 locationsNCT07361497
Recruiting
Effectiveness and Adverse-effect Switch Evaluation of Xanomeline and Trospium Chloride (KarXT)
Schizophrenia
Bristol-Myers Squibb1,500 enrolled45 locationsNCT07379827
Recruiting
A Study in Participants With Active Systemic Lupus Erythematosus With Inadequate Response to Glucocorticoids and ≥2 Immunosuppressants
Systemic Lupus Erythematosus (SLE)
Bristol-Myers Squibb223 enrolled54 locationsNCT07175285
Recruiting
Phase 3
A Study to Evaluate Safety and Efficacy of KarXT + KarX-EC as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-5)
Alzheimer DiseasePsychosis
Bristol-Myers Squibb325 enrolled20 locationsNCT06947941
Recruiting
Phase 2
A Study of CC-97540 (BMS-986353 or Zola-cel), CD19-Targeted NEX-T CAR T Cells, in Participants With Active SLE Despite Immunosuppressants (Breakfree-SLE)
Lupus Erythematosus, SystemicLupus Nephritis
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company89 enrolled93 locationsNCT07015983
Recruiting
Phase 2Phase 3
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
Non-small Cell Lung Cancer
Bristol-Myers Squibb596 enrolled186 locationsNCT07100080
Recruiting
Phase 2Phase 3
Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy
Urothelial Cancer
Bristol-Myers Squibb470 enrolled160 locationsNCT07106762
Recruiting
Phase 1
A Study to Evaluate the Safety, Tolerability, and Efficacy of Escalating Doses of BMS-986463 in Participants With Select Advanced Malignant Tumors.
Non-small Cell Lung Cancer (NSCLC)High-grade Serous Ovarian Carcinoma (HGSOC)Uterine Serous Carcinoma (USC)
Bristol-Myers Squibb240 enrolled17 locationsNCT06476808
Recruiting
Phase 2Phase 3
A Study Investigating Oral Ozanimod (RPC1063) in Pediatric Participants With Moderate to Severe Active Ulcerative Colitis
Colitis Ulcerative
Bristol-Myers Squibb120 enrolled90 locationsNCT05076175
Recruiting
Phase 3
A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Schizophrenia in Adolescents (EMERGENT TEEN)
Schizophrenia
Bristol-Myers Squibb166 enrolled44 locationsNCT07288567
Recruiting
Phase 2
Pan Tumor Rollover Study
Cancer
Bristol-Myers Squibb1,500 enrolled399 locationsNCT03899155
Recruiting
Phase 3
A Study to Evaluate the Long-term Safety and Tolerability of KarXT and KarX-EC for the Treatment of Schizophrenia and Autism-Related Irritability in Adolescents, Respectively
SchizophreniaAutism-Related Irritability
Karuna Therapeutics, Inc., a Bristol Myers Squibb company400 enrolled55 locationsNCT07424404
Recruiting
Phase 3
A Study to Evaluate the Benefits and Risks of Conversion of Existing Adolescent Kidney Transplant Recipients Aged 12 to <18 Years to a Belatacept-based Immunosuppressive Regimen as Compared to Continuation of a Calcineurin Inhibitor-based Regimen, and Their Adherence to Immunosuppressive Medications
Renal Allograft Recipients
Bristol-Myers Squibb102 enrolled38 locationsNCT04877288
Recruiting
Phase 2
Study to Evaluate Safety, Tolerability and Drug Levels of BMS-986435/MYK-224 in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF)
Heart Failure
Bristol-Myers Squibb208 enrolled117 locationsNCT06122779
Recruiting
Phase 3
A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)
Follicular Lymphoma
Celgene400 enrolled160 locationsNCT06911502